Report: Annual VC investment in genomics companies rises 142% since 2016

Genomics companies in the U.S. received $2.52 billion in venture capital funding in 2017, up 142 percent from $1.04 billion in 2016, according to a joint report by PwC and CB Insights.

Advertisement

The majority of the $2.52 billion in funding, roughly $1.7 billion, went toward companies focused on disease diagnosis. The second most-funded genomics sector was biotechnology at $550 million.

Here are the five genomics companies that received the most VC funding during the fourth quarter of 2017.

1. Menlo Park, Calif.-based Grail: $238 million

2. South San Francisco, Calif.-based Counsyl: $80 million

3. Baltimore-based Personal Genome Diagnostics: $65 million

4. Burlingame, Calif.-based Color Genomics: $37 million

5. Atlanta-based Prelude Fertility: $10 million

More articles on data analytics & precision medicine:
Report: 5 states with highest, lowest demand for data science jobs
Indiana U to launch statewide addiction database project
Survey: More than 80% of payers integrate social determinants of health data into programs

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.